The global Vaccines Market is estimated to be valued at USD 54.50 billion in 2025 and is projected to reach USD 111.3 billion by 2035, registering a compound annual growth rate (CAGR) of 7.4% over the forecast period

Metric	Value
Market Size in 2025	USD 54.50 billion
Projected Market Size in 2035	USD 111.3 billion
CAGR (2025 to 2035)	7.4%

Country-Wise Outlook

Country	CAGR (2025 to 2035)
United States	6.7%

Country	CAGR (2025 to 2035)
United Kingdom	6.2%

Country	CAGR (2025 to 2035)
European Union	6.4%

Country	CAGR (2025 to 2035)
Japan	6.1%

Country	CAGR (2025 to 2035)
South Korea	6.6%

The Preventive Vaccines Market report segments the industry into By Vaccine Type (Live/Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, mRNA Vaccines, Other Vaccine Types), By Disease Type (Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Mumps, and Rubella (MMR), COVID-19, Other Disease Types), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America).

Snapshot img

Vaccines Market Size 2025-2029

The vaccines market size is forecast to increase by USD 160.22 billion at a CAGR of 23.1% between 2024 and 2029.

The market is experiencing significant growth, driven by increased funding for research and development, leading to the launch of new vaccines. One of the most promising trends in this market is the development of nanoparticle vaccines, which offer enhanced immunogenicity and improved delivery systems. This trend is particularly evident in the development of nanoparticle vaccines, which offer enhanced efficacy and safety. However, the high cost of research, development, and manufacturing poses a significant challenge for market players. Examples include the inactivated polio vaccine (IPV) and influenza vaccine. These costs can be attributed to the complex production processes involved in vaccine creation, as well as the need for rigorous clinical trials to ensure safety and efficacy. 
However, the high cost of vaccine research, development, and manufacturing remains a significant challenge for market participants. Despite this, the market presents numerous opportunities for companies seeking to capitalize on the growing demand for vaccines, particularly in emerging economies with rising healthcare expenditures. Strategic partnerships, collaborations, and acquisitions are key strategies for companies looking to navigate the competitive landscape and stay ahead of the curve.
Overall, the market is poised for continued growth, with significant opportunities for innovation and investment in the coming years. Companies that can effectively address the challenges of cost and regulatory compliance while delivering high-quality, effective vaccines will be well-positioned to succeed.

What will be the Size of the Vaccines Market during the forecast period?

Request Free Sample

The market driven by the continuous development of immunization programs and the pursuit of vaccine equity. Immunological memory, antibody response, and cost-effectiveness analysis are key factors influencing market growth. Vaccine supply chain, efficacy testing, preservation, patent, and licensing are essential aspects of the market. Nanotechnology and universal vaccines are emerging trends, aiming to improve vaccine accessibility and quality control. Vaccine manufacturing, regulatory approval, and economic impact are crucial elements in the market, with intellectual property, vaccine shelf life, and vaccine development pipeline being significant factors.
Vaccine innovation and vaccine safety monitoring are essential for addressing disease burden and ensuring potency, stability, and sterility. Vaccine logistics and vaccine stability are critical for successful distribution and administration, while vaccine safety monitoring emphasizes the importance of ongoing surveillance and immune response assessment. 

How is this Vaccines Industry segmented?

The vaccines industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Subunit vaccines
  Live attenuated vaccines
  Inactivated vaccines
  Toxoid vaccines
  Others


End-user

  Hospitals
  Clinics


Technology

  mRNA vaccines
  Viral vector vaccines
  Protein based vaccines
  DNA vaccines
  Others


Route Of Administration

  Intramuscular
  Subcutaneous
  Oral
  Intranasal
  Others


Disease Type

  Influenza
  Human papillomavirus
  Hepatitis
  Measles
  mumps
  rubella
  Others


Age Group

  Pediatric
  Adult
  Adolescent
  Geriatric


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

By Type Insights

The subunit vaccines segment is estimated to witness significant growth during the forecast period.

Subunit vaccines, integral components of the healthcare system's disease prevention strategy, employ specific antigenic pieces of a pathogen, such as proteins, sugars, or capsids, to induce a robust immune response. These vaccines, including the mRNA vaccines, are designed to target specific components of the pathogen, making them highly effective in preventing infections. The development process involves identifying and isolating these antigenic components, followed by formulation and rigorous testing to ensure safety and efficacy. For instance, in the realm of disease outbreak prevention, a phase 3 trial for the subunit TB vaccine candidate M72/AS01E was initiated in March 2024 in South Africa.

This trial aims to evaluate the vaccine's efficacy in preventing the progression from latent TB to active pulmonary TB, contributing to herd immunity and ultimately, disease surveillance and vaccine distribution within the healthcare system.

The Vaccines Market report segments the industry into By Technology (Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, mRNA Vaccines, Recombinant Vaccines, Toxoid Vaccines, and more), By Type (Monovalent Vaccines, Multivalent Vaccines), By Disease Indication (DTP, Hepatitis, Herpes Zoster, HPV, Influenza, and more), By Route of Administration (Oral Administration, and more), By End-User, and By Geography.

The global vaccine market size was valued at USD 59.83 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 136.46 Billion by 2033, exhibiting a CAGR of 9.12% during 2025-2033. Asia-Pacific currently dominates the market, holding a significant market share of over 38.9% in 2024. The implementation of stringent regulations promoting vaccination adoption among individuals, several advances in biotechnology and vaccine development techniques, and growing health awareness among the population about the importance of vaccination are some of the major factors propelling the market.

The global cancer vaccines market is estimated to reach a valuation of USD 11.29 billion in 2025. It is expected to reach USD 27.95 billion by 2035, reflecting a CAGR of 12% during the forecast period between 2025 and 2035.

Metrics	Values
Industry Size (2025E)	USD 11.29 billion
Industry Value (2035F)	USD 27.95 billion
CAGR	12%

The global veterinary vaccines market is projected to expand from USD 9.92 billion in 2025 to USD 16.34 billion by 2035, reflecting a CAGR of 5.2%.

Attributes	Key Insights
Estimated Size, 2025	USD 9.92 billion
Projected Size, 2035	USD 16.34 billion
Value-based CAGR (2025 to 2035)	5.2%

Country-wise Insights

Countries	Value CAGR (2025 to 2035)
USA	6.1%
China	7.9%
Germany	5.0%
UK	5.7%
Japan	4.5%
India	7.5%

The COVID-19 Vaccine Market Report is Segmented by Technology Platform (mRNA Vaccines, Viral Vector Vaccines, and More), Valency (Monovalent Original, Bivalent Dual Strain, and More), End User (Government Immunization Programs, Hospitals & Clinics, Retail & Chain Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

The mRNA vaccine and therapeutics market size is estimated to be worth USD 9 billion in 2024 and is projected to be USD 1.99 billion by 2035, representing a CAGR of -23% during the forecast period from 2024 to 2035

The global vaccine market was valued at USD 68.07 Billion in 2024. The industry is expected to grow at a CAGR of 10.50% during the forecast period of 2025-2034 to attain a valuation of USD 184.75 Billion by 2034.

According to Cognitive Market Research, the global Inactivated Vaccines Market size will be USD 42514.8 million in 2025. It will expand at a compound annual growth rate (CAGR) of 8.00% from 2025 to 2033.

North America held the major market share for more than 37% of the global revenue with a market size of USD 15730.48 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.8% from 2025 to 2033.
Europe accounted for a market share of over 29% of the global revenue with a market size of USD 12329.29 million.
APAC held a market share of around 24% of the global revenue with a market size of USD 10203.55 million in 2025 and will grow at a compound annual growth rate (CAGR) of 10.0% from 2025 to 2033.
South America has a market share of more than 3.8% of the global revenue with a market size of USD 1615.56 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2025 to 2033.
Middle East had a market share of around 4.00% of the global revenue and was estimated at a market size of USD 1700.59 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.3% from 2025 to 2033.
Africa had a market share of around 2.20% of the global revenue and was estimated at a market size of USD 935.33 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2033.
Radiation Method is the fastest growing segment of the Inactivated Vaccines Market industry

Market Dynamics of Inactivated Vaccines Market

Key Drivers for Inactivated Vaccines Market

Increasing prevalence of infectious diseases globally fuels the market demand

The growing global burden of infectious diseases such as influenza, hepatitis, rabies, polio, and emerging zoonotic infections has significantly bolstered the demand for inactivated vaccines. According to the World Health Organization (WHO), the seasonal influenza affects about 1 billion people worldwide annually, causing 3 to 5 million severe cases and 290,000 to 650,000 deaths. It spreads via respiratory droplets and surfaces, with symptoms like fever and cough appearing within 1 to 4 days. Vaccination is the best prevention, recommended yearly for everyone over six months, especially high-risk groups. Flu seasons peak in winter months in temperate regions and occur year-round in tropical areas. These vaccines are particularly preferred in population groups requiring high safety profiles, including children, the elderly, and immunocompromised individuals. The resurgence of certain preventable diseases, owing to declining vaccination rates in some regions and the emergence of new viral strains, has further necessitated reliable and safe immunization options. Governments and international bodies such as the World Health Organization and UNICEF continue to emphasize immunization through national and regional programs, further propelling market demand. The increased frequency of epidemics and pandemics has also reinforced the need for scalable and broadly applicable inactivated vaccine solutions.

https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)

Expanding geriatric population with higher susceptibility to infections is expected to drive the market

The global rise in the aging population has emerged as a critical factor driving the growth of the inactivated vaccines market. Elderly individuals are more susceptible to various infectious diseases due to immunosenescence, an age-related decline in immune function. As a result, they require effective yet safe vaccines that do not pose risks of replication-induced complications, making inactivated vaccines an optimal choice. Moreover, increasing life expectancy and greater healthcare access among the elderly are contributing to higher vaccination rates. Healthcare providers are also proactively recommending inactivated vaccines as part of preventive care strategies for the aging population. Government immunization schedules in many countries now include inactivated vaccines targeting diseases like influenza and pneumococcal infections specifically for older adults.

Restraint Factor for the Inactivated Vaccines Market

High cost and longer production timelines for inactivated vaccines limit market growth

The manufacturing of inactivated vaccines involves complex procedures, including pathogen cultivation, inactivation, purification, formulation, and rigorous quality control, which substantially increase production...

The global pediatric vaccines market size reached USD 39.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 72.7 Billion by 2033, exhibiting a growth rate (CAGR) of 6.89% during 2025-2033. The growing conduction of vaccination programs, increasing focus on combination vaccines, and rising partnerships between pharmaceutical companies and healthcare organizations for fast-tracking the development and distribution of vaccines are some of the major factors propelling the market.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Historical Years	2019-2024
Market Size in 2024	USD 39.7 Billion
Market Forecast in 2033	USD 72.7 Billion
Market Growth Rate 2025-2033	6.89%

IMARC Group provides an analysis of the key trends in each segment of the global pediatric vaccines market report, along with forecasts at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on type, technology, and application.

The global H1N1 vaccines market size reached USD 3.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.6 Billion by 2033, exhibiting a growth rate (CAGR) of 4.03% during 2025-2033. The increasing healthcare concerns, significant medical advancements, improving healthcare systems, and rising awareness about the importance of H1N1 vaccines are some of the major factors propelling the market.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Historical Years	2019-2024
Market Size in 2024	USD 3.9 Billion
Market Forecast in 2033	USD 5.6 Billion
Market Growth Rate 2025-2033	4.03%

IMARC Group provides an analysis of the key trends in each segment of the global H1N1 vaccines market report, along with forecasts at the global and regional levels from 2025-2033. Our report has categorized the market based on vaccine type, key brands and market type.

• The global industry was valued at US$ 21.7 Bn in 2023
• It is projected to grow at a CAGR of -4.3% from 2023 to 2034 and reach more than US$ 9.6 Bn by the end of 2034

Market Introduction

Attribute	Detail
Drivers	Increase in Investments in mRNA Vaccines and Significant Innovations Growth in Emphasis on Cancer Treatment

Regional Outlook of mRNA Vaccine Industry

Attribute	Detail
Leading Region	North America

Global mRNA Vaccine Market Snapshot

Attribute	Detail
Market Value in 2023	US$ 21.7 Bn
Forecast (Value) in 2034	US$ 9.6 Bn
Growth Rate (CAGR)	-4.3%
Forecast Period	2024-2034
Historical Data Available for	2020-2022
Quantitative Units	US$ Mn for Value
Market Analysis	It provides segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape	Market share analysis by company (2022) Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Market Segmentation	Application COVID-19 Others End-user Government Entities Private Hospitals & Clinics Others (Pharmacies etc.)
Regions Covered	North America Latin America Europe Asia Pacific Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain China India Japan Australia & New Zealand Brazil Mexico South Africa GCC Countries
Companies Profiled	Pfizer, Inc. Moderna Inc. Novartis AG Sanofi Arcturus Gennova Biopharmaceuticals Ltd Aimei Vaccine Co., Ltd Other Prominent Players
Customization Scope	Available upon request
Pricing	Available upon request

The Viral Vaccines Market is Segmented by Form (Liquid Vaccines and Lyophilized Vaccines), Type (Live-Attenuated, Inactivated, and More), Approach (Therapeutic and Preventive), Age Group (Pediatric, Adult, and Geriatric), Distribution Channel (Public and Private) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market and Forecasts are Provided in Terms of Value (USD).

Anti-infective vaccine market is expected to grow at constant state, which is likely to amount USD 64,317.8 million in the year 2025 and estimated to grow at CAGR of 11.8%, at USD 196,222.0 million by the year 2035. One such foremost driving factor behind the growth is the increasing rate of infectious disease and the increasing need for vaccination program worldwide. The anti-infective vaccines avert a lot of infectious diseases caused by bacteria, viruses, fungus and parasites.

Metric	Value
Market Size (2024E)	USD 64,317.8 million
Market Value (2031F)	USD 196,222.0 million
CAGR (2025 to 2035)	11.8%

Country-wise Insights

Country	CAGR (2025 to 2035)
United States	11.8%

Country	CAGR (2025 to 2035)
United Kingdom	12.2%

Region	CAGR (2025 to 2035)
Europe an Union	11.9%

Country	CAGR (2025 to 2035)
Japan	11.5%

Country	CAGR (2025 to 2035)
South Korea	12.0%

Segmentation Outlook - Anti-Infective Vaccines Market

By Type	Market Share (2025)
Inactivated Vaccines	46.3%

By Application	Market Share (2025)
Viral Diseases	58.6%

Competitive Outlook

Company Name	Estimated Market Share (%)
GlaxoSmithKline (GSK)	20-25%
Sanofi	15-20%
Merck & Co.	12-15%
Pfizer Inc.	10-12%
Other Companies (combined)	28-43%

• The global industry was valued at US$ 40.6 Bn in 2023
• It is expected to grow at a CAGR of 5.7% from 2024 to 2034 and reach US$ 74.8 Bn by the end of 2034

Inactivated Vaccines Market Overview

Attribute	Detail
Market Drivers	Rise in Incidence of Infectious Diseases Increasing Number of Clinical Research Activities

Regional Analysis

Attribute	Detail
Leading Region	North America

Inactivated Vaccines Market Snapshot

Attribute	Detail
Market Size in 2023	US$ 40.6 Bn
Market Forecast (Value) in 2034	US$ 74.8 Bn
Growth Rate (CAGR)	5.7%
Forecast Period	2024-2034
Historical Data Available for	2020-2022
Quantitative Units	US$ Bn for Value
Market Analysis	It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape	Market share analysis by company (2023) Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Market Segmentation	Vaccine Type Viral Vaccine Bacterial Vaccine Method of Inactivation Solvent Detergent Method Radiation Method pH Concentration Others (Heat Inactivation, etc.) Route of Administration Oral Subcutaneous Intravenous End-user Hospitals Specialty Clinics Homecare Settings Others (Research Centers, etc.)
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain China India Japan Australia & New Zealand Brazil Mexico South Africa GCC
Companies Profiled	GSK plc Novartis AG Mylan N.V. Sanofi S.A. Boehringer Ingelheim International GmbH Merck & Co., Inc. F. Hoffmann-La Roche AG Bristol-Myers Squibb Company Bharat Biotech Serum Institute of India INOVIO Pharmaceuticals, Inc.
Customization Scope	Available Upon Request
Pricing	Available Upon Request

Snapshot img

Travel Vaccines Market Size 2025-2029

The travel vaccines market size is forecast to increase by USD 7.05 billion, at a CAGR of 10.7% between 2024 and 2029.

Major Market Trends & Insights

North America dominated the market and accounted for a 46% growth during the forecast period.
By the Disease Type - Influenza segment was valued at USD 3.44 billion in 2023
By the End-user - Adult vaccines segment accounted for the largest market revenue share in 2023

Market Size & Forecast

Market Opportunities: USD 112.15 billion
Market Future Opportunities: USD 7.05 billion 
CAGR : 10.7%
North America: Largest market in 2023

Market Summary

The market is a significant sector within the healthcare industry, demonstrating continuous growth and evolution. According to various market research, the demand for travel vaccines is on the rise, with an estimated 250 million international travelers in 2020. This number is projected to reach 380 million by 2027, representing a substantial increase. Travelers' changing demographics and increased global connectivity contribute to this market expansion. For instance, an aging population and the rise of adventure tourism are key factors driving the need for diverse travel vaccines. Moreover, the market is witnessing the emergence of new vaccine types, such as combination vaccines, which offer enhanced protection against multiple diseases.
The market's dynamism is further fueled by advancements in technology, enabling the development of more effective and convenient vaccine delivery methods. For example, the use of microneedle patches and oral vaccines is gaining popularity due to their ease of administration and improved patient compliance. Despite these positive trends, challenges persist, including the lack of comprehensive vaccine coverage in some health plans and the ongoing impact of the COVID-19 pandemic on travel vaccination services. Nonetheless, the market's potential for growth remains strong, with opportunities for collaboration between stakeholders, including pharmaceutical companies, travel agencies, and healthcare providers.

What will be the Size of the Travel Vaccines Market during the forecast period?

Explore market size, adoption trends, and growth potential for travel vaccines market Request Free Sample

Travel vaccines represent a significant segment within the healthcare industry, with current market participation exceeding 20%. This figure underscores the importance of travel vaccines in safeguarding the health of globally mobile populations. Looking ahead, market expansion is anticipated to surpass 15% annually, driven by increasing awareness of disease prevention and the continuous development of innovative vaccine formulations. The market demonstrates a dynamic equilibrium between vaccine efficacy and patient compliance. For instance, in 2020, vaccine recommendations for hepatitis A and typhoid fever reached 90% and 70%, respectively, reflecting high levels of adherence. In contrast, compliance for yellow fever and rabies vaccines stood at 60% and 40%, respectively.
This disparity underscores the importance of effective vaccine education and public health initiatives to boost compliance rates and ultimately improve disease prevention. Moreover, advancements in vaccine manufacturing, cold chain management, and adjuvant systems have led to increased vaccine availability and efficacy. For example, cellular immunity responses to certain vaccines have shown promising results, leading to enhanced protection against various diseases. These advancements not only contribute to the market's growth but also improve overall traveler health and safety.

How is this Travel Vaccines Industry segmented?

The travel vaccines industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Disease Type

  Influenza
  Diptheria
  Hepatitis
  Typhoid and others


End-user

  Adult vaccines
  Pediatric vaccines


Type

  Outbound
  Inbound


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

By Disease Type Insights

The influenza segment is estimated to witness significant growth during the forecast period.

The market, specifically for influenza, is experiencing substantial expansion due to several factors. The resurgence of leisure and corporate travel to pre-pandemic levels and the increasing health awareness among travelers are primary drivers. Influenza vaccines are easily accessible, as they are widely available at pharmacies, healthcare facilities, and workplaces, making administration convenient for travelers. Moreover, disease surveilla

In 2024, the Vaccines Market was valued at $83.38 Bn and is projected to reach $115.08 Bn by 2030, driven by the rising aging population globally.

The global viral vaccines market size is projected to grow from USD 57.72 billion in 2025 to USD 79.27 billion by 2033, exhibiting a CAGR of 4.05%.
Report Scope:

Report Metric	Details
Market Size in 2024	USD 55.07 Billion
Market Size in 2025	USD 57.72 Billion
Market Size in 2033	USD 79.27 Billion
CAGR	4.05% (2025-2033)
Base Year for Estimation	2024
Historical Data	2021-2023
Forecast Period	2025-2033
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered	By Types,By Consumer groups,By Disease Indication,By Route of Administration,By Region.
Geographies Covered	North America, Europe, APAC, Middle East and Africa, LATAM,
Countries Covered	U.S., Canada, U.K., Germany, France, Spain, Italy, Russia, Nordic, Benelux, China, Korea, Japan, India, Australia, Singapore, Taiwan, South East Asia, UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Brazil, Mexico, Argentina, Chile, Colombia,